ArticleFrontiers in immunology2026
Machine learning diagnostic model integrating ultrasound features and immune-inflammatory biomarkers for identifying papillary thyroid carcinoma in patients with Hashimoto's thyroiditis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiating papillary thyroid carcinoma (PTC) from benign nodules in patients with Hashimoto's thyroiditis (HT) remains a significant clinical challenge due to the complex sonographic background and overlapping inflammatory features. This study aimed to develop and validate an interpretable machine learning (ML) model integrating ultrasound features and immune-inflammatory biomarkers for PTC identification in HT patients. Methods: A multicenter retrospective study was conducted, enrolling 1, 200 HT patients with thyroid nodules from Wuxi People's Hospital (January 2020 to December 2025), randomly divided into a training cohort (n=840) and a testing cohort (n=360). An independent external validation cohort (n=550) was recruited from Nanjing Gaochun People's Hospital during the same period. A total of 38 candidate variables, including clinical characteristics, ultrasound features, and immune-inflammatory indices, were evaluated. Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate logistic regression were utilized for feature selection. Seven ML algorithms were compared to construct the optimal predictive model. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA). SHapley Additive exPlanations (SHAP) were employed to enhance model interpretability. Results: Six variables were selected as the most informative features for predicting the pathological outcome of PTC: Systemic Immune-Inflammation Index (SII), Thyroid Peroxidase Antibody (TPOAb), pseudonodule formation, shear wave elastography maximum elasticity (SWE-Emax), vascularity grade, and TI-RADS category. The Random Forest (RF) model demonstrated superior performance, achieving an AUC of 0.907 in the training cohort, 0.872 in the testing cohort, and 0.823 in the external validation cohort. Calibration curves and DCA confirmed the model's high clinical net benefit. SHAP analysis revealed that SII, TPOAb, and pseudonodule formation were the top three contributing features. A web-based risk calculator was subsequently deployed for clinical application. Conclusion: The proposed interpretable RF model effectively integrates ultrasound features and immune-inflammatory biomarkers to accurately identify PTC in HT patients. The developed web-based calculator provides a practical, non-invasive tool to assist clinicians in personalized decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.